AL-8326 is under clinical development by Advenchen Laboratories and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AL-8326’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AL-8326 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AL-8326 overview

AL-8326 is under development for the treatment of advanced solid tumors including glioblastoma multiforme (GBM), small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, endometrial cancer, cervical cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, head and neck cancer, prostate cancer, kidney cancer, bladder cancer, gastrointestinal stromal tumor and cholangiocarcinoma. It is administered through oral route. The drug candidate is a multikinase inhibitor that acts by targeting Aurora B, FGFR (fibroblast growth factor receptor) and VEGFR (vascular endothelial growth factor receptor).

Advenchen Laboratories overview

Advenchen Laboratories is a pharmaceutical company that offers healthcare solutions. The company conducts pharmaceutical research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others. Advenchen Laboratories provides services such as producing inhibitors for the treatment of human colon cancer, liver cancer, gastric cancer, lungs and breast cancer, among others. Advenchen Laboratories also provides customized chemical intermediate services. The company operates in China and the US. Advenchen Laboratories is headquartered in Moorpark, California, the US.

Quick View AL-8326 LOA Data

Report Segments
  • Innovator
Drug Name
  • AL-8326
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.